The merger of India’s Biocon Biologics and Viatris’ biosimilar business are reported to be in advanced stages.
Viatris was formed in November 2020, when Mylan merged with Upjohn, Pfizer's off-patent medicine division. This occurred after the companies received the go-ahead from authorities in Europe, Australia and New Zealand [1].
It is expected that Biocon will buy Viatris’ biosimilar business in an equity-cash-deal, handing over US$1.5 billion to Viatris in a merger that will create a business worth an estimated US$10 billion. Biocon aims to hold a controlling majority stake in the business and will also look for an initial public offering (IPO) for the merged entity based on this valuation.
Biocon and Viatris already have a business relationship as they are exclusive partners on a broad portfolio of biosimilars and insulin analogues. For example, the companies recently launched two versions of their interchangeable biosimilar Semglee (insulin glargine) in the US market [2].
In late 2021, Biocon entered into a vaccine alliance deal with Adar Poonawalla’s Serum Institute in India [2]. Herein, a 15% stake of Biocon’s biosimilar unit was sold to the institute to enable access to millions of vaccine doses, including COVID-19 shots. The deal valued Biocon Biologics at US$4.9 billion.
Related articles
Biocon Biologics partners to improve global access to cancer treatments and insulin
FDA approves insulin glargine biosimilar Semglee
| LATIN AMERICAN FORUM The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View this week’s headline article: Biosimilares aprobados en Colombia Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative. LATIN AMERICAN FORUM Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Vea el artículo principal de esta semana: Biosimilares aprobados en Colombia !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Mylan-Upjohn merger receives go ahead from Europe, Australia and New Zealand [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 11]. Available from: www.gabionline.net/pharma-news/Mylan-Upjohn-merger-receives-go-ahead-from-Europe-Australia-and-New-Zealand
2. GaBI Online - Generics and Biosimilars Initiative. Viatris/Biocon launch two versions of Semglee to accommodate rebates [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 11]. Available from: www.gabionline.net/biosimilars/general/viatris-biocon-launch-two-versions-of-semglee-to-accommodate-rebates
3. GaBI Online - Generics and Biosimilars Initiative. Biocon Biologics and Serum Institute Life Sciences partnership [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2022 Feb 11]. Available from: www.gabionline.net/pharma-news/biocon-biologics-and-serum-institute-life-sciences-partnership
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2022 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment